Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxcarbazepine + gabapentin
- Development stage
- Unknown
- Lead developer
- Rehman Medical Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oxcarbazepine + gabapentin is an investigational combination of two anticonvulsant small molecules being evaluated for the treatment of idiopathic trigeminal neuralgia. Oxcarbazepine, a keto-derivative of carbamazepine, primarily blocks voltage-gated sodium channels to stabilize hyperexcited neuronal membranes. Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing neuronal excitability and pain signaling. This dual-mechanism approach aims to provide superior pain relief compared to monotherapy by targeting multiple pathways involved in neuropathic pain. The combination is currently being studied in a prospective trial by the Rehman Medical Institute.
- Other names
- gabapentin + oxcarbazepine
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)CACNA2D2 (α2δ-2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on oxcarbazepine + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxcarbazepine + gabapentin.